Women aged 65 and older undergoing chemotherapy for breast cancer have a higher risk of experiencing a decline in their ability to function physically, according to a new study published in the Journal of the American Geriatrics Society.
Women aged 65 and older undergoing chemotherapy for breast cancer have a higher risk of experiencing a decline in their ability to function physically, according to a new study published in the Journal of the American Geriatrics Society.
The effect of chemotherapy on functional status can be critical for older adults, as declining function can inhibit the ability to live independently and perform daily activities. Additionally, previous studies have shown that older individuals with breast cancer who demonstrated a decline in physical function in the first 2 years after diagnosis had poorer 10-year survival.
Therefore, researchers measured patients’ ability to perform daily activities after receiving chemotherapy. Their goal was to identify why some women recovered their ability to function normally and others did not.
The researchers analyzed data from a previous study that included 635 women aged 65 years or older who had been diagnosed with breast cancer.
The researchers then asked the study participants the following questions:
According to the findings, short-term decline in physical function appeared to be common among older adults treated with chemotherapy. Forty-two percent of patients reported a decrease in their ability to function from pre-chemotherapy to the end of treatment and 30% experienced a decline in their ability to function from before they started treatment to 12 months later.
Among the patients who experienced physical function decline from the beginning to end of treatment, some returned to their normal functioning levels. According to the study, 47% of patients recovered to the activity level they previously had within 12 months after starting chemotherapy.
“In our study, about half of the patients who experienced functional decline were able to ‘bounce back’ to their former function, and we considered them to be physically resilient,” the researchers wrote. “We also learned that half of the patients were resistant to decline and maintained their functional status throughout treatment.”
Based on their findings, the researchers identified risk factors for functional decline 1 year after chemotherapy as fatigue, having difficulty breathing, being unmarried or lacking social support, and poor appetite, which could indicate poor nutrition and/or depression. They noted that encouraging diet and exercise programs and behavior interventions for older adults being treated with chemotherapy could help increase their ability to recover functioning abilities.
“This study provides insight into the incidence of functional decline in older adults with breast cancer receiving adjuvant chemotherapy, a group that has been understudied,” the researchers concluded in the study. “It also provides insight into potential risk factors for functional decline and lack of resilience that can be targeted for interventions.”
References
Hurria A, Soto-Perez-de-Celis E, Allred JB, et al. Functional decline in resilience in older women receiving adjuvant chemotherapy for breast cancer. Journal of the American Geriatrics Society. 2018;doi:10.1111/jgs.15493.
Does Chemotherapy Harm Ability to Function for Older Women with Breast Cancer [research summary]. Health in Aging’s website. https://www.healthinaging.org/blog/does-chemotherapy-harm-ability-to-function-for-older-women-with-breast-cancer/. Accessed August 29, 2018.
A version of the article was published in Specialty Pharmacy Times® as “Study: Identify Risk Factors in Women with Breast Cancer to Minimize Chemo-Related Functional Decline”
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Cilta-cel Demonstrates 99.4% ORR in Lenalidomide-Refractory Myeloma
Multidisciplinary Infrastructure Streamlines Cancer Care During Drug Shortages
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
Inconsistent Symptom Clusters Warrant Routine Assessments in Older Patients With Cancer
2 Commerce Drive
Cranbury, NJ 08512